← Back
Tenax Therapeutics
TENX · listed on Nasdaq · worth $67.36 million
$1.80
+0.56% on Nov 2
One insider bought $550.7K of Tenax Therapeutics stock in the last two weeks. The buyer was ADAR1 Capital Management.
Different buyers at once3 insiders bought, and 3 big investors reported new stakes, within a month · Sep 17
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
29.9M shares
80% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, seven insiders bought Tenax Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
ADAR1 Capital Management
Bought $1.27M on Aug 21 — 716,369 shares at $1.77, held through a trust or family, 15% of what they now own.
No earlier purchases to measure
Director
Declan Doogan
Bought $101.8K on Sep 16 — 53,000 shares at $1.92, 96% of what they now own.
First purchase we have on file
Interim CFO
Thomas Mcgauley
Bought $36.1K on Nov 17, 2025 — 5,000 shares at $7.23, held through a trust or family, 100% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Tenax Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateMillennium Management LLC3.6%Oct 15Reported stake, oldest first: 5.8% (Aug 18) → 3.6% (Oct 15)
Filed by someone who owns 5% or more and does not plan to influence the company. · updateSphera Funds Management7.1%Oct 13Reported stake, oldest first: 5.3% (Aug 27) → 7.1% (Oct 13)
Filed by someone who owns 5% or more and does not plan to influence the company. · updateDellora Investments LP5.5%Oct 9
Filed by someone who owns 5% or more and does not plan to influence the company. · updateIng Groep NV0.0%Sep 11
Filed by someone who owns 5% or more and does not plan to influence the company.ADAR1 Capital Management14.0%Sep 8
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for Tenax Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 21BoughtADAR1 Capital ManagementOct 21 · 10% owner+4.5%via a trust or family331,979 @ $1.66$550.7K
Oct 21BoughtADAR1 Capital ManagementOct 21 · Traded Oct 20 · 10% owner+3.6%via a trust or family254,342 @ $1.60$405.7K
Oct 21BoughtADAR1 Capital ManagementOct 21 · Traded Oct 19 · 10% owner+4.9%via a trust or family336,528 @ $1.51$507K
21 more with Pro →Analysts, earnings and news
Analysts' price target
$12.56 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 4 quarters above
Q2 '26−$0.35 a share+$0.01
Q1 '26−$0.35 a share+$0.05
Q4 '25−$0.38 a share+$0.03
Q3 '25−$0.40 a share+$0.72